CRDF (Cardiff Oncology) Float Percentage Of Total Shares Outstanding: 97.65% (As of Jun. 30, 2026)


CRDF Cardiff Oncology Inc CRDF
53 GF Score
Price $1.28
GF Value $1.48
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Float Percentage Of Total Shares Outstanding?

Cardiff Oncology CRDF -0.39% 53 Float Percentage Of Total Shares Outstanding is 97.65% as of Jun. 30, 2026. GuruFocus rates CRDF with a GF Score™ of 53/100 and a GF Value™ of $1.48 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cardiff Oncology's float shares is 66.77 Mil. Cardiff Oncology's total shares outstanding is 68.37 Mil. Cardiff Oncology's float percentage of total shares outstanding is 97.65%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cardiff Oncology's Insider Ownership is 3.77%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cardiff Oncology's Institutional Ownership is 41.41%.

CRDF
53GF Score
Cardiff Oncology Inc CRDF
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cardiff Oncology's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=66.77/68.37
=97.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 97.65% mean?
Cardiff Oncology (CRDF) has a Float Percentage Of Total Shares Outstanding of 97.65% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Float Percentage Of Total Shares Outstanding too high?
Cardiff Oncology's current Float Percentage Of Total Shares Outstanding is 97.65%. Overall, Cardiff Oncology has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Float Percentage Of Total Shares Outstanding compare to MAIA and TELO?
Cardiff Oncology's Float Percentage Of Total Shares Outstanding of 97.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Float Percentage Of Total Shares Outstanding is 97.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.48, compared to a current price of $1.28 — trading 13.9% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 97.65%. Cardiff Oncology's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Float Percentage Of Total Shares Outstanding is 97.65% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.28 is trading 13.9% below its estimated GF Value™ of $1.48. GuruFocus considers Cardiff Oncology to be Modestly Undervalued.

Key valuation signals for CRDF:

  • Float Percentage Of Total Shares Outstanding: 97.65%
  • GF Value™: $1.48 vs. price of $1.28 (13.9% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
53GF Score

Get the complete analysis for CRDF

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.28
Price
$1.48
GF Value